DMRA
Damora Therapeutics, Inc.
$27.53
-2.47 (-8.23%)
At close · Jul 8
Market Cap
$1.89B
Shares
61,553,194
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.53
Open$29.71
Day$27.18–30.35
52W$2.45–38.33
Avg vol 30d773K
Short int1.3M · 2.1% float · 3.4d
Short vol63%
DataOct 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+14%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
70%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+32%
trailing
6-month return
+18%
trailing
YTD return
+20%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
+261% holders QoQ · +51 funds added
Insider flow
Distributing
Net -$7.3K over 90 days · 100% sells
Short interest
Falling
2.13% of float · ▼ -6.6% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
65 holders — near 1-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
EPS growth
+121%
Y/Y
Free cash flow
$-6.9M
Valuation
P/E 5.8
below peers
Balance sheet
$257.6M
net cash
Quant / Vol
risk profile
Volatility
475%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
70%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $24 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
+261% holders QoQ · +51 funds added
Insider flow
Distributing
Net -$7.3K over 90 days · 100% sells
Short interest
Falling
2.13% of float · ▼ -6.6% MoM · 3.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
65 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $28 · 70%
52-wk high $38
vs 200-day avg +26%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMRA
this stock
Damora Therapeutics, Inc.
|
$1.89B | +19.6% | — | 5.8 | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMRA | +5.8% | +31.7% | +18.2% | +5.8% | +19.6% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +6.0% | +30.8% | +10.7% | +6.0% | +10.3% |